The drug has been approved for use in conjunction with two different hepatitis C drugs, pegylated-interferon and ribavirin.
The combined dosage is indicated for the patients who are new to treatment, and for people who were treated previously but who did not achieve a sustained viral response (SVR, or viral cure).
The Health Canada approval was backed by the results of Phase 3 studies which demonstrated that people who received Incivek combination treatment achieved higher rates of viral cure (sustained viral response, or SVR) compared to those who received pegylated-interferon and ribavirin alone.